Downregulation of galectin-3 causes a decrease in uPAR levels and inhibits the proliferation, migration and invasion of hepatocellular carcinoma cells

Oncology Reports

Volumn 32, Issue 1, 2014, Pages 411-418

  Zheng, Datong ^a,b   Hu, Zhenzhen ^b   He, Fan ^b   Gao, Caijie ^b   Xu, Lijian ^b   Zou, Han ^b   Wu, Zhiwei ^a   Jiang, Xiuqin ^b   Wang, Jianjun ^a  

^a NANJING UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Galectin 3; Hepatocellular carcinoma cells; Migration; Proliferation; uPAR

Indexed keywords

GALECTIN 3; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; UROKINASE RECEPTOR; 1,3 BUTADIENE DERIVATIVE; 1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; NITRILE; SMALL INTERFERING RNA;

ARTICLE; CARCINOMA CELL; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; GENE EXPRESSION; HEPATOCELLULAR CARCINOMA CELL LINE; HEPG2 CELL LINE; IN VITRO STUDY; LIVER CELL CARCINOMA; MIGRATION INHIBITION; MITOSIS INHIBITION; MOLECULAR PATHOLOGY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; GENE SILENCING; GENETICS; HUMAN; LIVER TUMOR; METABOLISM; PATHOLOGY; TUMOR CELL LINE; TUMOR INVASION;

BUTADIENES; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; GALECTIN 3; GENE KNOCKDOWN TECHNIQUES; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; MAP KINASE SIGNALING SYSTEM; NEOPLASM INVASIVENESS; NITRILES; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; RNA, SMALL INTERFERING;

EID: 84903118235     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2014.3170     Document Type: Article

References (50)

1. El-Serag HB, Mason AC and Key C: Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United States. Hepatology 33: 62-65, 2001. (Pubitemid 32016888)
2. Altekruse SF, McGlynn KA and Reichman ME: Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 27: 1485-1491, 2009.
3. Jemal A, Bray F, Center MM, et al: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
4. Carr BI: Hepatocellular carcinoma: current management and future trends. Gastroenterology 127: S218-S224, 2004.
5. Takenaka Y, Fukumori T and Raz A: Galectin-3 and metastasis. Glycoconj J 19: 543-549, 2004. (Pubitemid 38316528)
6. Radosavljevic G, Volarevic V, Jovanovic I, et al: The roles of Galectin-3 in autoimmunity and tumor progression. Immunol Res 52: 100-110, 2012.
7. Saussez S, Camby I, Toubeau G and Kiss R: Galectins as modulators of tumor progression in head and neck squamous cell carcinomas. Head Neck 29: 874-884, 2007. (Pubitemid 350303676)
8. McCubrey JA, Steelman LS, Abrams SL, et al: Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul 46: 249-279, 2006. (Pubitemid 44301348)
9. Wesley UV, Vemuganti R, Ayvaci ER and Dempsey RJ: Galectin-3 enhances angiogenic and migratory potential of microglial cells via modulation of integrin linked kinase signaling. Brain Res 1496: 1-9, 2013.
10. Friedrichs J, Manninen A, Muller DJ and Helenius J: Galectin-3 regulates integrin alpha2beta1-mediated adhesion to collagen-I and -IV. J Biol Chem 283: 32264-32272, 2008.
11. Piccolo E, Tinari N, Semeraro D, et al: LGALS3BP, lectin galactoside-binding soluble 3 binding protein, induces vascular endothelial growth factor in human breast cancer cells and promotes angiogenesis. J Mol Med 91: 83-94, 2013.
12. Nangia-Makker P, Wang Y, Raz T, et al: Cleavage of galectin-3 by matrix metalloproteases induces angiogenesis in breast cancer. Int J Cancer 127: 2530-2541, 2010.
13. Rossi ED, Straccia P, Palumbo M, et al: Diagnostic and prognostic role of HBME-1, galectin-3, and beta-catenin in poorly differentiated and anaplastic thyroid carcinomas. Appl Immunohistochem Mol Morphol 21: 237-241, 2013.
14. Yamaki S, Fujii T, Yajima R, et al: Clinicopathological significance of decreased galectin-3 expression and the long-term prognosis in patients with breast cancer. Surg Today 43: 901-905, 2013.
15. Cui W, Sang W, Zheng S, et al: Usefulness of cytokeratin-19, galectin-3, and Hector Battifora mesothelial-1 in the diagnosis of benign and malignant thyroid nodules. Clin Lab 58: 673-680, 2012.
16. Blanquart C, Gueugnon F, Nguyen JM, et al: CCL2, galectin-3, and SMRP combination improves the diagnosis of mesothelioma in pleural effusions. J Thorac Oncol 7: 883-889, 2012.
17. Paunovic I, Isic T, Havelka M, et al: Combined immunohistochemistry for thyroid peroxidase, galectin-3, CK19 and HBME-1 in differential diagnosis of thyroid tumors. APMIS 120: 368-379, 2012.
18. Chiu CG, Strugnell SS, Griffith OL, et al: Diagnostic utility of galectin-3 in thyroid cancer. Am J Pathol 176: 2067-2081, 2010.
19. Matsuda Y, Yamagiwa Y, Fukushima K, Ueno Y and Shimosegawa T: Expression of galectin-3 involved in prognosis of patients with hepatocellular carcinoma. Hepatol Res 38: 1098-1111, 2008.
20. Baldini E, Sorrenti S, D'Armiento E, et al: The urokinase plasminogen activating system in thyroid cancer: clinical implications. G Chir 33: 305-310, 2012.
21. Laerum OD, Ovrebo K, Skarstein A, et al: Prognosis in adenocarcinomas of lower oesophagus, gastro-oesophageal junction and cardia evaluated by uPAR-immunohistochemistry. Int J Cancer 131: 558-569, 2012.
22. Jacobsen B and Ploug M: The urokinase receptor and its structural homologue C4.4A in human cancer: expression, prognosis and pharmacological inhibition. Curr Med Chem 15: 2559-2573, 2008.
23. Smith HW and Marshall CJ: Regulation of cell signalling by uPAR. Nat Rev Mol Cell Biol 11: 23-36, 2010.
24. Dass K, Ahmad A, Azmi AS, Sarkar SH and Sarkar FH: Evolving role of uPA/uPAR system in human cancers. Cancer Treat Rev 34: 122-136, 2008.
25. Mani T, Wang F, Knabe WE, et al: Small-molecule inhibition of the uPAR.uPA interaction: Synthesis, biochemical, cellular, in vivo pharmacokinetics and efficacy studies in breast cancer metastasis. Bioorg Med Chem 21: 2145-2155, 2013.
26. Lebeau AM, Duriseti S, Murphy ST, et al: Targeting uPAR with antagonistic recombinant human antibodies in aggressive breast cancer. Cancer Res 73: 2070-2081, 2013.
27. Soydinc HO, Duranyildiz D, Guney N, Derin D and Yasasever V: Utility of serum and urine uPAR levels for diagnosis of breast cancer. Asian Pac J Cancer Prev 13: 2887-2889, 2012.
28. Park JS, Park JH, Khoi PN, Joo YE and Jung YD: MSP-induced RON activation upregulates uPAR expression and cell invasiveness via MAPK, AP-1 and NF-kappaB signals in gastric cancer cells. Carcinogenesis 32: 175-181, 2011.
29. Baek MK, Park JS, Park JH, et al: Lithocholic acid upregulates uPAR and cell invasiveness via MAPK and AP-1 signaling in colon cancer cells. Cancer Lett 290: 123-128, 2010.
30. Yoon SY, Lee YJ, Seo JH, et al: uPAR expression under hypoxic conditions depends on iNOS modulated ERK phosphorylation in the MDA-MB-231 breast carcinoma cell line. Cell Res 16: 75-81, 2006.
31. Bessard A, Fremin C, Ezan F, Coutant A and Baffet G: MEK/ ERK-dependent uPAR expression is required for motility via phosphorylation of P70S6K in human hepatocarcinoma cells. J Cell Physiol 212: 526-536, 2007. (Pubitemid 47025643)
32. Wu KL, Huang EY, Jhu EW, et al: Overexpression of galectin-3 enhances migration of colon cancer cells related to activation of the K-Ras-Raf-Erk1/2 pathway. J Gastroenterol 48: 350-359, 2013.
33. Song S, Ji B, Ramachandran V, et al: Overexpressed galectin-3 in pancreatic cancer induces cell proliferation and invasion by binding Ras and activating Ras signaling. PLoS One 7: e42699, 2012.
34. Weng CJ, Tsai CM, Chen YC, et al: Evaluation of the association of urokinase plasminogen activator system gene polymorphisms with susceptibility and pathological development of hepatocellular carcinoma. Ann Surg Oncol 17: 3394-3401, 2010.
35. Nangia-Makker P, Nakahara S, Hogan V and Raz A: Galectin-3 in apoptosis, a novel therapeutic target. J Bioenerg Biomembr 39: 79-84, 2007. (Pubitemid 46877176)
36. Fukumori T, Kanayama HO and Raz A: The role of galectin-3 in cancer drug resistance. Drug Resist Updat 10: 101-108, 2007. (Pubitemid 47031053)
37. Song YK, Billiar TR and Lee YJ: Role of galectin-3 in breast cancer metastasis: involvement of nitric oxide. Am J Pathol 160: 1069-1075, 2002. (Pubitemid 34224593)
38. Bresalier RS, Yan PS, Byrd JC, Lotan R and Raz A: Expression of the endogenous galactose-binding protein galectin-3 correlates with the malignant potential of tumors in the central nervous system. Cancer 80: 776-787, 1997. (Pubitemid 27339834)
39. Cvejic DS, Savin SB, Petrovic IM, et al: Galectin-3 expression in papillary thyroid carcinoma: relation to histomorphologic growth pattern, lymph node metastasis, extrathyroid invasion, and tumor size. Head Neck 27: 1049-1055, 2005. (Pubitemid 41705582)
40. John CM, Leffler H, Kahl-Knutsson B, Svensson I and Jarvis GA: Truncated galectin-3 inhibits tumor growth and metastasis in orthotopic nude mouse model of human breast cancer. Clin Cancer Res 9: 2374-2383, 2003. (Pubitemid 36687665)
41. Kobayashi T, Shimura T, Yajima T, et al: Transient gene silencing of galectin-3 suppresses pancreatic cancer cell migration and invasion through degradation of beta-catenin. Int J Cancer 129: 2775-2786, 2011.
42. Alge-Priglinger CS, Andre S, Schoeffl H, et al: Negative regulation of RPE cell attachment by carbohydrate-dependent cell surface binding of galectin-3 and inhibition of the ERK-MAPK pathway. Biochimie 93: 477-488, 2011.
43. Shalom-Feuerstein R, Cooks T, Raz A and Kloog Y: Galectin-3 regulates a molecular switch from N-Ras to K-Ras usage in human breast carcinoma cells. Cancer Res 65: 7292-7300, 2005. (Pubitemid 41161261)
44. Boscher C and Nabi IR: Galectin-3- and phospho-caveolin- 1-dependent outside-in integrin signaling mediates the EGF motogenic response in mammary cancer cells. Mol Biol Cell 24: 2134-2145, 2013.
45. Santiago-Gomez A, Barrasa JI, Olmo N, et al: 4F2hc-silencing impairs tumorigenicity of HeLa cells via modulation of galectin-3 and beta-catenin signaling, and MMP-2 expression. Biochim Biophys Acta 1833: 2045-2056, 2013.
46. Sant'ana JM, Chammas R, Liu FT, et al: Activation of the Wnt/beta-catenin signaling pathway during oral carcinogenesis process is not influenced by the absence of galectin-3 in mice. Anticancer Res 31: 2805-2811, 2011.
47. Dakeng S, Duangmano S, Jiratchariyakul W, et al: Inhibition of Wnt signaling by cucurbitacin B in breast cancer cells: reduction of Wnt-associated proteins and reduced translocation of galectin- 3-mediated beta-catenin to the nucleus. J Cell Biochem 113: 49-60, 2012.
48. Kwaan HC and McMahon B: The role of plasminogen-plasmin system in cancer. Cancer Treat Res 148: 43-66, 2009.
49. Zheng Q, Tang ZY, Xue Q, et al: Invasion and metastasis of hepatocellular carcinoma in relation to urokinase-type plasminogen activator, its receptor and inhibitor. J Cancer Res Clin Oncol 126: 641-646,2000.
50. Falasca M: PI3K/Akt signalling pathway specific inhibitors: a novel strategy to sensitize cancer cells to anti-cancer drugs. Curr Pharm Des 16: 1410-1416, 2010.